Peptide Therapeutics Market Development Strategies Include Strategic -

The global peptide therapeutics market size was estimated at USD 117.26 billion in 2024 and is anticipated to grow at a CAGR of 10.77% from 2025 to 2030. The rising prevalence of cancer and metabolic disorders, including osteoporosis, obesity, and diabetes, is expected to drive the adoption of peptide therapeutics in the coming years. The increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, underscores the need for affordable and effective treatment options.

Moreover, strong presence of peptide therapeutic drugs in clinical pipeline for different indications is expected to boost market growth over the forecast period. For instance, Zealand Pharma has a strong pipeline portfolio of peptide therapeutics for targeting metabolic, gastrointestinal, and cardiovascular diseases. Its most advanced candidate, Survodutide (Phase 3), a dual GLP-1 and glucagon receptor agonist, is positioned for obesity treatment, while Glepaglutide (Registration Phase) is nearing potential approval for short bowel syndrome. Petrelintide (Phase 2) is being explored for cardiovascular and metabolic disorders, while Dapiglutide (Phase 1) and ZP6590 (Phase 1) focus on metabolic and gastrointestinal conditions. Additionally, ZP9830 (Phase 1) and ZP10068 (Preclinical) highlight the company’s commitment to early-stage peptide innovation. Zealand Pharma’s diverse and advancing pipeline positions it as a strong contender in the growing peptide therapeutics market, with promising near-term commercialization prospects and long-term growth potential.

The rising prevalence of various cancers and the growing need for effective treatment options are expected to drive market growth. According to the WHO, in 2022, an estimated 20 million new cancer cases were reported globally, resulting in 9.7 million deaths. Approximately 53.5 million people were living within five years of a cancer diagnosis. Around one in five individuals develop cancer in their lifetime, with approximately one in nine men and one in twelve women succumbing to the disease. Peptide therapeutics offer early-stage cancer treatment, improving disease management and reducing mortality. The increasing demand for efficient, fast-acting therapeutics is anticipated to further fuel market expansion.

The market is expected to grow at a strong CAGR over the forecast period as companies focus on developing novel drugs. Extensive research and development (R&D) efforts are underway to create treatments for target diseases and expand market share. Peptide therapeutics R&D primarily targets metabolic disorders, followed by oncology and infectious diseases. Regulatory frameworks are becoming more stringent, with agencies such as the FDA and EMA implementing higher standards for efficacy, safety, and quality. These bodies are also evaluating new guidelines to streamline the approval process for peptide therapeutics.

However, challenges remain in peptide synthesis and purification. The limited capacity of solid-phase reactors hinders the production of long peptides, impacting chemical functionalization and resin swelling. Additionally, the incorporation of unnatural amino acids and complex 3D conformations further complicates separation and purification, increasing manufacturing difficulties.

Get a preview of the latest developments in the Global Peptide Therapeutics Market! Download your FREE sample PDF today and explore key data and trends

Regional Insights

The North America Peptide Therapeutics market maintains a leading position in 2024 with share of 60.21% globally in 2024, driven by the rising prevalence of cancer, metabolic disorders, and rare diseases. The growing adoption of synthetic and recombinant peptides, alongside advancements in drug delivery technologies, is enhancing therapeutic efficacy. Expansion in biopharmaceutical R&D and regulatory approvals is supporting market growth. Hospital and retail pharmacies continue to be key distribution channels, with increasing demand for targeted peptide-based therapies.

Key Peptide Therapeutics Companies:

The following are the leading companies in the peptide therapeutics market. These companies collectively hold the largest market share and dictate industry trends.

Eli Lilly and Company
Pfizer Inc.
Amgen Inc.
Takeda Pharmaceutical Company Limited
AstraZeneca
Teva Pharmaceutical Industries Ltd.
Sanofi
Hoffmann-La Roche Ltd
Novartis AG
Novo Nordisk A/S
GSK plc
Ironwood Pharmaceuticals, Inc.
Radius Health, Inc. (Subsidiary of Gurnet Point Capital and Patient Square Capital)
Ipsen Pharma